As a hammer to force companies to negotiate, House Speaker Nancy Pelosi would impose steep sales taxes on the medications at issue. Overall, budget analysts estimated the legislation would cut industry revenues by $500 billion to $1 trillion over 10 years.
As open enrollment goes into the home stretch Thanksgiving week, critics say the new tool can create confusion by obscuring out-of-pocket costs that seniors should factor into their decisions.
The pharmaceutical giant says it needs additional manufacturing capacity to keep up with demand for current medicines and new drugs expected to emerge from its pipeline.
A Gallup-West Health poll finds that 66 percent of adults don’t believe the Trump administration has made any progress, or very much progress, in limiting the rising cost of prescription drugs.
President Trump is instead backing a bipartisan bill that would for the first time limit what seniors have to pay out of their own pockets for medications.
The company said Monday that it will close 150 Walgreens-run clinics by the end of the year, but it will keep open more than 200 that are run in partnership with health care providers.
Digging through old data to salvage a seemingly failed Alzheimer’s drug paid off big time for Biogen Inc., but at least one of its rivals has no plans to follow suit.
President Donald Trump and House Speaker Nancy Pelosi could hardly be more at odds—but behind the scenes, they’re still grasping at a bipartisan deal to lower the cost of prescription drugs.
Eli Lilly and Co. easily topped earnings expectations in the third quarter, but shares in the Indianapolis-based drug company tumbled nearly 5 percent Wednesday morning.
One day after three opioid distributors reached a $260 million tentative settlement with two Ohio counties, Indiana Attorney General Curtis Hill filed a lawsuit seeking damages from the same three companies.
Seven months after clinical trials for a promising Alzheimer’s drug were halted and the treatment was declared a failure, a new analysis suggests it was actually effective, and the company that makes it plans to move forward in securing federal approval.
The settlement means a high-profile trial in Ohio will not move forward, but it does not resolve more than 2,600 other lawsuits across the country seeking to hold the drug industry accountable for a crisis that has been linked to more than 400,000 U.S. deaths since 2000.
Outlines of a settlement call for $22 billion in cash over time plus up to $15 billion worth of overdose antidotes and treatment drugs, with distribution of those drugs valued at another $14 billion.
The drug, called pegilodecakin, had been seen as a promising treatment for one of the deadliest types of cancer, and was the lead product in Lilly’s $1.6 billion acquisition of Armo BioSciences last year.
Vice President Mike Pence stumped for President Trump’s proposed deal with Mexico and Canada during a rally Thursday at McAllister Machinery on the city’s southeast side.
The owner of Pace Air Freight, which specializes in truck transport of pharmaceutical products, is in the process of assembling land it doesn’t already own, including parcels owned by Indianapolis International Airport.
Indiana Attorney General Curtis Hill is among the 29 attorneys general across the country backing a proposed settlement with OxyContin maker Purdue Pharma, calling the agreement a “significant breakthrough in our important fight against the opioid crisis.”
Paul Elmer, 68, of Fishers, was sentenced Wednesday in U.S. District Court in Indianapolis, six months after a jury found him guilty of nine counts of adulterating compounded drugs and one count of conspiracy.
Purdue Pharma may have just set the starting point for determining what it will cost dozens of pharmaceutical companies to resolve legal liability over their role in creating the U.S. opioid epidemic.
By Thursday, half of the nation’s state attorneys general said they would reject a tentative deal crafted by the other half, and many criticized the terms as grossly insufficient.
